×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NTLA – intellia therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NTLA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/28
05:45 am
ntla
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA
Medium
Report
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA
3/27
07:48 pm
ntla
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion.
Medium
Report
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion.
3/27
12:48 pm
ntla
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline
Low
Report
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline
3/27
05:45 am
ntla
The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Low
Report
The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
3/26
05:14 pm
ntla
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
Low
Report
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
3/26
04:26 pm
ntla
Intellia Therapeutics, Inc. Shareholders are Reminded of the Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against NTLA
Low
Report
Intellia Therapeutics, Inc. Shareholders are Reminded of the Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against NTLA
3/26
04:00 pm
ntla
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Low
Report
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
3/26
03:40 pm
ntla
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Low
Report
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Date
Time
Symbol
Company Name
Action
%Chg
2/27/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-4.7%
intellia therapeutics, inc.
2/27/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-2.3%
intellia therapeutics, inc.
2/27/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-4.6%
intellia therapeutics, inc.
2/27/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-4.9%
intellia therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/4
04:43 pm
ntla
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Clark Eliana
Low
Report
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Clark Eliana
3/4
04:41 pm
ntla
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: LEONARD JOHN M
Low
Report
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: LEONARD JOHN M
3/4
04:34 pm
ntla
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Dulac Edward J III
Low
Report
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Dulac Edward J III
3/4
04:29 pm
ntla
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Dube Michael P
Low
Report
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Dube Michael P
3/4
04:26 pm
ntla
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Lebwohl David
Low
Report
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Lebwohl David
3/4
04:24 pm
ntla
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Schultes Birgit C
Low
Report
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: Schultes Birgit C
3/4
04:22 pm
ntla
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: BASTA JAMES
Low
Report
Form 4 Intellia Therapeutics, For: Mar 01 Filed by: BASTA JAMES
2/28
04:03 pm
ntla
Form S-8 Intellia Therapeutics,
Medium
Report
Form S-8 Intellia Therapeutics,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/27
Intellia Therapeutics, Inc. (NTLA) Q4 2019 Earnings Call Transcript [The Motley Fool]
17.1%
10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%
2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%
11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%
4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%
6/7 Form EFFECT Intellia Therapeutics, 5.6%
2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%
10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%
3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%
7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%
10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%
2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%
11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%
4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%
6/7 Form EFFECT Intellia Therapeutics, 5.6%
2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%
10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%
3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%
7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%
TOP News Decliners
3/13
Form 8-K Intellia Therapeutics, For: Mar 12
-17.6%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: